To gauge the effects of long-term ARN22089 treatment on tumor growth, we inoculated mice with one BRAF mutant PDX that was known to have consistent growth properties and began treating the mice with ARN22089 with 0, 10, or 25 mg/kg intravenous (i.v.)twice a week (BIW) until control tumors reached endpoint. This evidence concerns the gene BRAF and neoplasm.